Market CapCHF26.6m

Last Close CHF2.26

Polyphor is a development stage company focused on oncology and antibiotics. Lead programme balixafortide is a CXCR4 inhibitor in Phase III for breast cancer. Data are expected in 2021. It has approval to initiate its Phase I programme of inhaled murepavadin to treat P. aeruginosa infections in CF patients.

More Polyphor content >

Investment summary

Polyphor is a development-stage company focused on oncology and antibiotics. Its lead programme is balixafortide, a C-X-C chemokine receptor type 4 (CXCR4) inhibitor currently in a randomised-controlled Phase III trial in 432 previously treated human epidermal growth factor receptor 2 (HER2) negative advanced breast cancer patients. The company announced in June that the co-primary endpoint of the study, objective response rate, was not met. The company is in the process of winding down the study and is conducting a strategic review which is expected to be completed by the end of August.

Y/E Dec
Revenue (CHFm)
P/E (x)
P/CF (x)
2019A 0.0 (64.9) (64.2) (581.19) N/A N/A
2020A 14.3 (42.4) (43.0) (386.81) N/A N/A
2021E 0.0 (44.8) (45.4) (398.54) N/A N/A
2022E 0.0 (41.1) (41.7) (362.63) N/A N/A
Industry outlook

According to the National Cancer Institute, 78% of the estimated 276,480 new cases of breast cancer every year are HER2 negative. For those who are HER2 negative and hormone-receptor positive (68% of breast cancers), chemotherapy remains the standard of care in over 90% of cases once past front-line therapy.

Last updated on 03/09/2021
Content on Polyphor
Polyphor – Phase III ORR data on track for Q221
Healthcare | Update | 9 March 2021
close up test tubes
Polyphor – executive interview
Healthcare | Edison TV | 18 November 2020
Polyphor – Balixafortide Phase III data coming soon
Healthcare | Initiation | 5 October 2020
close up test tubes
View more
Register to receive research on Polyphor as it is published
Share price graph
Balance sheet
Forecast net debt (CHFm) 10
Forecast gearing ratio (%) 34
Price performance
Actual 15.9 (67.7) (69.5)
Relative* 14.1 (69.9) (74.7)
52-week high/low CHF8.9/CHF1.6
*% relative to local index
Key management
Gökhan Batur CEO
Hernan Levett CFO
Martin Jakobovic Business planning analyst